

PRIOR AUTHORIZATION REQUEST FORM
OVERACTIVE BLADDER

 Myrbetriq[®], Toviaz[®]

For authorization, please answer each question and fax this form PLUS chart notes back to the U of U Health Plans Prior Authorization Department. Failure to submit clinical documentation to support this request will result in delay and/or denial of the request.

For Commercial Groups, Individual & Family Plans please fax request to 888-509-8142.

For Healthy U Medicaid, University of Utah Health Employees please fax request to 844-316-3655

If you have prior authorization questions, please call for assistance: Healthy U: 866-236-5935, University of Utah Health Employees: 866-861-6178, Individual & Family Plans : 855-869-4769, Commercial Groups: 855-859-4892

Date:	Member Name:	ID#:
DOB:	Gender:	Physician:
Office Phone:	Office Fax:	Office Contact:
Height/Weight:		

Member must try formulary preferred drugs before a request for a non-preferred drug may be considered. If treatment with preferred products has not been successful, you must submit which preferred products have been tried, dates of treatment, and reason for failure. Reasons for failure must meet the Health Plan medical necessity criteria.

 Product being request: Myrbetriq[®] (mirabegron), Toviaz[®] (fesoterodine)

Dosing/Frequency: _____

If the request is for reauthorization, proceed to reauthorization section

Questions	Yes	No	Comments/Notes
1. Does the member have a confirmed diagnosis of overactive bladder?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
2. Does the member have symptoms of urinary incontinence, urgency and urinary frequency?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
3. Has the member tried and failed behavioral therapies, such as bladder training, bladder control strategies, fluid management, etc.? (Not required in the setting of neurogenic bladder)	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Has the member tried and failed at least 3 other antimuscarinic agents, such as darifenacin, oxybutynin and tolterodine?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

REAUTHORIZATION

1. Is the request for reauthorization of therapy?	<input type="checkbox"/>	<input type="checkbox"/>	
2. Has the member's therapy been re-evaluated within the past 12 months?	<input type="checkbox"/>	<input type="checkbox"/>	
3. Has the therapy been shown to be effective with an improvement in condition?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation
4. Does the member show a continued medical need for the therapy?	<input type="checkbox"/>	<input type="checkbox"/>	Please provide documentation

What medications and/or treatment modalities have been tried in the past for this condition? Please document name of treatment, reason for failure, treatment dates, etc.

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.

Additional information:
Physician's Signature:

****Failure to submit clinical documentation to support this request will result in delay and/or denial of the request****

Policy PHARM-097
Origination Date: 01/22/2020
Reviewed/Revised Date: 03/25/2020
Next Review Date: 03/25/2021
Current Effective Date: 06/28/2020

Confidentiality Notice

This document and any accompanying document contain confidential information and is intended for the use of the individual or entity named on this transmission sheet. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or the taking of any action in reliance on the contents of this information is strictly prohibited and the document should be returned to this office immediately. If you have received this facsimile in error, please notify us by telephone immediately and destroy document received.